Literature DB >> 4005140

Antibody guided lymphangiography in the staging of cervical cancer.

A A Epenetos.   

Abstract

Iodine-123-labelled tumour associated monoclonal antibody HMFG2 was administered intralymphatically at a time that cannulation of pedal lymphatic vessels was performed for standard lymphangiography in 6 patients with cervical cancer. Gamma camera images were taken at 2 h and 24 h after injection of antibody and at a similar time that X-ray lymphangiography was performed. Five out of the 6 standard lymphangiograms were reported as normal whilst one showed definite evidence of metastasis. Antibody guided analysis of the abnormal lymphangiogram confirmed the presence of abnormality. Also, marked non-specific uptake of antibody was seen on all lymphangiograms. It is concluded that, in order for monoclonal antibody guided lymphangiography to become a useful adjunct to standard lymphangiography, further improvements are needed to reduce non-specific uptake by normal lymphatics.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4005140      PMCID: PMC1977082          DOI: 10.1038/bjc.1985.125

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  7 in total

1.  The accuracy of lymphangiography in carcinoma of the uterine cervix.

Authors:  M S Piver; S Wallace; J R Castro
Journal:  Am J Roentgenol Radium Ther Nucl Med       Date:  1971-02

2.  Use of panels of monoclonal antibodies in the differential diagnosis of neuroblastoma and lymphoblastic disorders.

Authors:  J T Kemshead; A Goldman; J Fritschy; J S Malpas; J Pritchard
Journal:  Lancet       Date:  1983-01-01       Impact factor: 79.321

3.  Targeting of iodine-123-labelled tumour-associated monoclonal antibodies to ovarian, breast, and gastrointestinal tumours.

Authors:  A A Epenetos; K E Britton; S Mather; J Shepherd; M Granowska; J Taylor-Papadimitriou; C C Nimmon; H Durbin; L R Hawkins; J S Malpas; W F Bodmer
Journal:  Lancet       Date:  1982-11-06       Impact factor: 79.321

4.  Monoclonal antibodies in the lymphatics: selective delivery to lymph node metastases of a solid tumor.

Authors:  J N Weinstein; M A Steller; A M Keenan; D G Covell; M E Key; S M Sieber; R K Oldham; K M Hwang; R J Parker
Journal:  Science       Date:  1983-10-28       Impact factor: 47.728

5.  Location of metastatic breast carcinoma by a monoclonal antibody chelate labelled with indium-111.

Authors:  R M Rainsbury; R J Ott; J H Westwood; T S Kalirai; R C Coombes; V R McCready; A M Neville; J C Gazet
Journal:  Lancet       Date:  1983-10-22       Impact factor: 79.321

6.  Differentiation antigens expressed by epithelial cells in the lactating breast are also detectable in breast cancers.

Authors:  J Arklie; J Taylor-Papadimitrious; W Bodmer; M Egan; R Millis
Journal:  Int J Cancer       Date:  1981-07-15       Impact factor: 7.396

7.  Localization of I-131-labeled goat and primate anti-carcinoembryonic antigen(CEA) antibodies in patients with cancer.

Authors:  D C Sullivan; J S Silva; C E Cox; D E Haagensen; C C Harris; W H Briner; S A Wells
Journal:  Invest Radiol       Date:  1982 Jul-Aug       Impact factor: 6.016

  7 in total
  4 in total

1.  Antibody-guided lymphangiography in the staging of cervical cancer.

Authors:  N Saunders; M E Paterson; S Sherriff
Journal:  Br J Cancer       Date:  1986-05       Impact factor: 7.640

2.  Epitope analysis of monoclonal antibody NCRC-11 defined antigen isolated from human ovarian and breast carcinomas.

Authors:  M R Price; S Edwards; M Powell; R W Baldwin
Journal:  Br J Cancer       Date:  1986-09       Impact factor: 7.640

3.  Placental-type alkaline phosphatase in cervical neoplasia.

Authors:  P J McLaughlin; P H Warne; G E Hutchinson; P M Johnson; D F Tucker
Journal:  Br J Cancer       Date:  1987-02       Impact factor: 7.640

4.  The detection of axillary lymph node metastases from breast cancer by radiolabelled monoclonal antibodies: a prospective study.

Authors:  J J Tjandra; N P Sacks; C H Thompson; M J Leyden; S A Stacker; M Lichtenstein; I S Russell; J P Collins; J T Andrews; G A Pietersz
Journal:  Br J Cancer       Date:  1989-02       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.